Incretin ReviewResearch · Context · Care

Publication record

The source record

Official pages, original research and clearly identified evidence limits.

Source notes

Scientific sources checked October 21, 2026. Earlier research and provider sources retain their dated histories below. Provider pages document advertised terms. Study summaries identify the scope of our review.

  1. Lincoff et al. — SELECT cardiovascular outcomes trialOriginal randomized trial; abstract reviewed · Checked 2026-10-21
  2. FDA — AEMS Public Dashboard FAQPublic safety-data limitations
  3. FDA — interpreting postmarket safety surveillanceRegulatory surveillance explanation
  4. FDA — concerns with unapproved GLP-1 drugsRegulatory and safety context · Checked 2026-10-21
  5. FDA — compounding questions and answersCompounded-product status
  6. CoreAge Rx — semaglutide offerProvider advertisement
  7. CoreAge Rx — tirzepatide offerProvider advertisement
  8. CoreAge Rx — pricing and plansProvider billing terms
  9. SuperHealthy Rx — GLP-1 offerProvider advertisement
  10. Likeness Rx — GLP-1 plansProvider offer and renewal terms
  11. Ro — Body membershipProvider membership advertisement
  12. WeightWatchers — Med+ programProvider membership advertisement
  13. LillyDirect — access optionsManufacturer access program
  14. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - PubMedPrimary source; original trial abstracts used for trial summaries
  15. Clinical Trial ParticipationPrimary health resource; checked October 5, 2026
  16. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity - PubMedPrimary source; original trial abstracts used for trial summaries · Checked 2026-10-21
  17. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - PubMedPrimary health resource; checked October 5, 2026
  18. Weight Loss Care for Women, Built to Last | HersProvider public offer; checked October 5, 2026
  19. FAQs | HersProvider public offer; checked October 5, 2026
  20. Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
  21. Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
  22. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossPrimary health resource; checked October 5, 2026
  23. Calibrate Weight Loss Pricing: How Much Does Calibrate Cost? | CalibrateProvider public offer; checked October 5, 2026
  24. Online weight loss medication with or without insuranceProvider public offer; checked October 5, 2026
  25. OurView Health: Plan prices and care claimsProvider public information; checked October 15, 2026
  26. OurView Health: Compounded semaglutide offerProvider public information; checked October 15, 2026
  27. OurView Health: Compounded tirzepatide offerProvider public information; checked October 15, 2026
  28. OurView Health: Payment, pharmacy and provider FAQProvider public information; checked October 15, 2026
  29. OurView Health: Return and refund policyProvider public information; checked October 15, 2026
  30. OurView Health: General terms; January 9, 2026Provider public information; checked October 15, 2026
  31. Queen RX: Program description and expanded FAQProvider public information; checked October 15, 2026
  32. Queen RX: Rendered three-month package menu and product FAQProvider public information; checked October 15, 2026
  33. Queen RX: Operator, pharmacy, provider and general payment termsProvider public information; checked October 15, 2026
  34. Queen RX: Refund policy; November 30, 2024Provider public information; checked October 15, 2026
  35. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.Indexed original research abstract · Checked 2026-10-21
  36. FDA approves treatment for serious liver disease known as MASHOfficial FDA page read through web tool; historical approval announcement, not complete current labeling · Checked 2026-10-21
  37. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.Primary research or official information · Checked 2026-10-21
  38. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.Indexed original research abstract · Checked 2026-10-21
  39. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.Indexed original research abstract · Checked 2026-10-21
  40. DailyMed - FOUNDAYO- orforglipron tablet, film coatedOfficial page retrieved in full · Checked 2026-10-21